@Article{Gerkowicz2008,
journal="Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii",
issn="1642-395X",
volume="25",
number="6",
year="2008",
title="Original paperThe use of biological agents in the treatment of psoriasis",
abstract="Nail involvement occurs in 10-50% of patients with psoriasis vulgaris. Nail psoriasis tends to be refractory to the treatment, and becomes an important issue due to the psychological and therapeutic problems. Therefore research is done to find alternative therapeutic methods for patients who did not achieve any improvement after conventional therapies (both local and systemic). Recently there have been a few publications that announced the possibilities of using new immunomodulating drugs in the treatment of nail psoriasis. Recent studies have proved the efficacy and safety of infliximab and alefacept as therapeutic agents for nail psoriasis. The clinical trials which evaluate the therapeutic benefits of using etanercept, efalizumab and adalimumab in the treatment of nail psoriasis are still ongoing. This article is a review of literature regarding the efficacy and safety of these modern biological agents in the treatment of nail psoriasis.",
author="Gerkowicz, Agnieszka
and Chodorowska, Grażyna
and Chodorowski, Jakub",
pages="283--288",
url="https://www.termedia.pl/Original-paper-The-use-of-biological-agents-in-the-treatment-of-psoriasis,7,11691,1,1.html"
}